vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and PennyMac Mortgage Investment Trust (PMT). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $93.6M, roughly 1.3× PennyMac Mortgage Investment Trust). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs 3.3%, a 52.6% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -13.3%). Over the past eight quarters, PennyMac Mortgage Investment Trust's revenue compounded faster (12.3% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
NATR vs PMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $93.6M |
| Net Profit | $4.1M | $52.4M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | 38.6% |
| Net Margin | 3.3% | 56.0% |
| Revenue YoY | 4.7% | -13.3% |
| Net Profit YoY | 1379.4% | 12.5% |
| EPS (diluted) | $0.23 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $93.6M | ||
| Q3 25 | $128.3M | $99.2M | ||
| Q2 25 | $114.8M | $70.2M | ||
| Q1 25 | $113.2M | $44.5M | ||
| Q4 24 | $118.2M | $107.9M | ||
| Q3 24 | $114.6M | $80.9M | ||
| Q2 24 | $110.6M | $71.2M | ||
| Q1 24 | $111.0M | $74.2M |
| Q4 25 | $4.1M | $52.4M | ||
| Q3 25 | $5.3M | $58.3M | ||
| Q2 25 | $5.3M | $7.5M | ||
| Q1 25 | $4.7M | $9.7M | ||
| Q4 24 | $-321.0K | $46.5M | ||
| Q3 24 | $4.3M | $41.4M | ||
| Q2 24 | $1.3M | $25.4M | ||
| Q1 24 | $2.3M | $47.6M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | 38.6% | ||
| Q3 25 | 7.0% | 47.4% | ||
| Q2 25 | 3.7% | 24.2% | ||
| Q1 25 | 5.4% | -14.2% | ||
| Q4 24 | 3.8% | 51.1% | ||
| Q3 24 | 4.6% | 32.8% | ||
| Q2 24 | 5.1% | 40.2% | ||
| Q1 24 | 4.2% | 43.6% |
| Q4 25 | 3.3% | 56.0% | ||
| Q3 25 | 4.2% | 58.7% | ||
| Q2 25 | 4.6% | 10.7% | ||
| Q1 25 | 4.2% | 21.8% | ||
| Q4 24 | -0.3% | 43.1% | ||
| Q3 24 | 3.8% | 51.2% | ||
| Q2 24 | 1.2% | 35.7% | ||
| Q1 24 | 2.1% | 64.2% |
| Q4 25 | $0.23 | $0.49 | ||
| Q3 25 | $0.30 | $0.55 | ||
| Q2 25 | $0.28 | $-0.04 | ||
| Q1 25 | $0.25 | $-0.01 | ||
| Q4 24 | $-0.02 | $0.45 | ||
| Q3 24 | $0.23 | $0.36 | ||
| Q2 24 | $0.07 | $0.17 | ||
| Q1 24 | $0.12 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $190.5M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $161.6M | $1.9B |
| Total Assets | $261.1M | $21.3B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $190.5M | ||
| Q3 25 | $95.6M | $181.0M | ||
| Q2 25 | $81.3M | $108.6M | ||
| Q1 25 | $86.5M | $204.2M | ||
| Q4 24 | $84.7M | $103.2M | ||
| Q3 24 | $78.7M | $102.8M | ||
| Q2 24 | $68.7M | $336.3M | ||
| Q1 24 | $77.8M | $343.3M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $299.0M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $968.4M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | $2.1M | $5.1B |
| Q4 25 | $161.6M | $1.9B | ||
| Q3 25 | $166.7M | $1.9B | ||
| Q2 25 | $163.7M | $1.9B | ||
| Q1 25 | $167.1M | $1.9B | ||
| Q4 24 | $161.0M | $1.9B | ||
| Q3 24 | $162.6M | $1.9B | ||
| Q2 24 | $156.4M | $1.9B | ||
| Q1 24 | $159.7M | $2.0B |
| Q4 25 | $261.1M | $21.3B | ||
| Q3 25 | $264.8M | $18.5B | ||
| Q2 25 | $254.9M | $16.8B | ||
| Q1 25 | $252.7M | $14.9B | ||
| Q4 24 | $240.9M | $14.4B | ||
| Q3 24 | $245.3M | $13.1B | ||
| Q2 24 | $235.8M | $12.1B | ||
| Q1 24 | $247.3M | $12.3B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 2.70× | ||
| Q2 24 | — | 2.76× | ||
| Q1 24 | 0.01× | 2.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $-7.2B |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | -137.76× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $-7.2B | ||
| Q3 25 | $18.5M | $-1.3B | ||
| Q2 25 | $4.3M | $-2.0B | ||
| Q1 25 | $2.6M | $-594.3M | ||
| Q4 24 | $12.2M | $-2.7B | ||
| Q3 24 | $9.6M | $-983.8M | ||
| Q2 24 | $1.3M | $243.8M | ||
| Q1 24 | $2.2M | $-342.4M |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 2.41× | -137.76× | ||
| Q3 25 | 3.46× | -22.26× | ||
| Q2 25 | 0.81× | -267.53× | ||
| Q1 25 | 0.55× | -61.39× | ||
| Q4 24 | — | -58.08× | ||
| Q3 24 | 2.21× | -23.76× | ||
| Q2 24 | 0.97× | 9.59× | ||
| Q1 24 | 0.94× | -7.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
